1. Pink Sheet
  2. >>Biosimilars & Generics
  3. >>Biosimilars

Transition Day In The US: 96 Drugs Make The Move To Biologics Regulation

 
• By Sue Sutter

Sanofi’s Lantus stands alone as the only insulin product still listed in the ‘Orange Book’ post-transition because it is referenced in Mylan/Biocon’s pending 505(b)(2) application for insulin glargine; the FDA said it stands ready to review biosimilar and interchangeable applications that reference the newly ‘deemed’ biologic products.

Open wooden door to the new world with green environment. Climate change concept.
US FDA’s door is now open to applications for biosimilar and interchangeable insulins. • Source: Shutterstock

On the day that almost 100 products switched from being regulated as drugs to biologics in the US – opening the door for the first time to applications for biosimilar and interchangeable versions – Sanofi’s Lantus (insulin glargine) stands alone as the only insulin product still listed in the “Orange Book.”

23 March was transition day for insulins, human growth hormone and other protein products originally approved as new drug applications

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Biosimilars & Generics